Chemomab Therapeutics Ltd. appointed new CEO

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(b) As previously reported by Chemomab Therapeutics Ltd. (the "Company") in its definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on September 17, 2021, the Company and Mr. Stephen Squinto, the Company's chairman of the board of directors (the "Board"), agreed that Mr. Squinto's term as chairman of the Board would lapse no later than June 30, 2022, and concurrent with Mr. Squinto's resignation, the Company's nominating and governance committee and Board would move to recommend that the Company's shareholders appoint Dr. Dale Pfost, the Company's Chief Executive Officer and Class III director, as Mr. Squinto's successor as chairman of the Board (or, alternatively, Dr. Pfost will have the right to identify a candidate to be appointed as chairman of the Board).


On December 12, 2021, the Company and Mr. Squinto mutually agreed that Mr. Squinto's resignation as the chairman of the Board will enter into effect on December 19, 2021.


Mr. Squinto indicated that this decision was not as a result of any disagreement with the Company or its board of directors nor any matter related to the Company's operations, policies or practices.


In accordance with the Israeli Companies Law, 5759-1999, the appointment of a chief executive officer to the position of chairman of the board of directors requires the approval of the company's nominating committee, board of directors and shareholders (pursuant to a special majority), in that order. On December 15, 2021, the nominating and governance committee and the Board each approved and recommended that the shareholders approve the appointment of Dr. Pfost as chairman of the Board. The Company intends to promptly pursue shareholder approval of Dr. Pfost's appointment to the position of chairman of the Board.